Mirum Pharmaceuticals (MIRM) Hits Its Primary Endpoint, Is The Stock Still Undervalued?

Mirum Pharmaceuticals (MIRM) just reported that its AZURE-1 Phase 3 trial for brelovitug in chronic hepatitis delta virus met the primary endpoint, supported by 48-week data showing deeper viral suppression and consistent safety.

Mirum Pharmaceuticals has had a weak run in the past month, with the 30-day share price return down 19.3% and the 90-day move down 36.5%, even though the 1-year total shareholder return is 12.3% and the 5-year total shareholder return is very large at about 4.7x. This points to long term momentum that contrasts with the recent pullback around these AZURE-1 and Atebrioz updates.

Scan beyond Mirum Pharmaceuticals and see how other rare disease players are reacting to similar catalysts by running the hand picked 19 high quality undiscovered gems right alongside this news.

Mirum Pharmaceuticals now trades at a sharp discount to both analyst targets and intrinsic value estimates, after a steep pullback on positive trial and approval news. The key question is where a fair entry point really lines up within that wide gap.

Most Popular Narrative: 44% Undervalued

Mirum Pharmaceuticals last closed at $81.43, while the most widely followed narrative anchors fair value at $145.79. The gap between price and story is wide and is driven by very specific growth and margin assumptions.

The expanding addressable patient population for Mirum's therapies, especially with the increased recognition and diagnosis of later-onset PFIC through broader use of genetic testing and heightened disease awareness, is driving higher-than-expected patient volumes. This growing patient base is expected to directly contribute to sustained top-line revenue growth.

See why 12 investors see Mirum Pharmaceuticals as 44% undervalued.

Result: Fair Value of $145.79 (UNDERVALUED)

Still, Mirum Pharmaceuticals relies heavily on Livmarli and faces regulatory timing risk around volixibat. Either factor could disrupt the current bullish narrative.

Find out about the key risks to this Mirum Pharmaceuticals narrative.

Next Steps

Mixed signals around Mirum Pharmaceuticals can easily sway sentiment, so move quickly, test those assumptions against the underlying numbers, and weigh both the 4 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Mirum Pharmaceuticals?

Do not stop with Mirum Pharmaceuticals when there are other focused opportunities that line up with different risk levels, income goals, and balance sheet strength.

• Target potential mispricing by reviewing companies that combine quality fundamentals with discounted valuations through the curated 27 high quality undervalued stocks.
• Strengthen your income stream by scanning for businesses with higher yields and resilient payouts inside the focused 7 dividend fortresses.
• Prioritise resilience by zeroing in on companies with robust finances using the hand built list of solid balance sheet and fundamentals (25 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com